The selective delivery of chemotherapeutic agents to their site of action should increase therapeutic effectiveness and limit side effects. Most drug therapies currently available, however, exhibit little, if any specificity. Many times, a drug has limited or no access to its intended site of action or is prematurely metabolized or excreted. In other instances, the drug travels rather freely throughout the body and not only acts on the desired target tissues but also causes undesirable effects on nontarget tissues. This lack of target specificity is attributable, for the most part, to the formidable barriers that the body presents to the successful delivery of a drug from its site of administration to its site of action: a drug normally encounters or must by pass various molecules, enzymes, cells, membranes, and organs before reaching its designated target.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Site-Specific Drug Delivery in US$ by following Product Segments.: Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel and other.
Company profiles are primarily based on public domain information including company
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm

Market Analysis and Insights: Global Site-Specific Drug Delivery Market
The global Site-Specific Drug Delivery market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Site-Specific Drug Delivery market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Site-Specific Drug Delivery market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Site-Specific Drug Delivery market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Site-Specific Drug Delivery market.

Global Site-Specific Drug Delivery Scope and Market Size
Site-Specific Drug Delivery market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Site-Specific Drug Delivery market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Other

Segment by Application
Fungal Infection Therapy
Cancer & Tumor Therapy
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm